A total of 43 innovative new medicines are anticipated to be approved or listed in Japan this year, according to a survey by Jiho. At the center of attention are some highly innovative, but probably ultra-expensive, gene therapies, as well…
BUSINESS
Novartis to Sell 14 Long-Listed Brands to Sun Pharma in Japan, Likely to Stop Aredia Sales
India’s Sun Pharmaceutical Industries has announced a US$293 million cash deal to buy Novartis’s 14 established brands in Japan, marking inroads into the Japanese ethical drug market, but the two companies’ local subsidiaries have remained mum on its details. Sun…
To read the full story
Related Article
- Sun Pharma Japan to Boost Sales Force, Development to Achieve 1.5-Fold Sales Growth by 2025
October 27, 2021
- Sun Pharma Poised to Raise Profile in Japan Dermatology Space, Generics and New Drugs Alike
January 25, 2019
- Sun Taps Mitsubishi Tanabe to Distribute Novartis’ 14 Established Brands
September 7, 2016
BUSINESS
- Daiichi Sankyo Sets Up Advanced Drug-Discovery Lab in San Diego
January 22, 2025
- Sanofi CEO Warns Off-Cycle Price Cuts Will Dilute Attractiveness of Japan Market
January 22, 2025
- DyDo’s 1st Drug Firdapse for LEMS Hits Japan Market
January 22, 2025
- ITP Drug Tavalisse Approved in South Korea: Kissei
January 22, 2025
- Kobayashi Pharma to Revamp Management under New President
January 22, 2025
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…